Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 49
- Registration Number
- NCT01154881
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers
Phase 1
Completed
- Conditions
- Acquired Bleeding DisorderCardiac Surgery Requiring Cardiopulmonary BypassHealthy
- Interventions
- Drug: placebo
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01153997
A Trial Comparing the Effect of NN1250 After Different Routes of Injection in Healthy Subjects
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT01151072
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 65
- Registration Number
- NCT01138501
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Izmit, Turkey
A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 38
- Registration Number
- NCT01138488
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany
Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 143
- Registration Number
- NCT01135992
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Olympia, Washington, United States
A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22
- Registration Number
- NCT01135927
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 39
- Registration Number
- NCT01134224
A Comparison Between Two Formulations of NN5401 in Healthy Subjects
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 26
- Registration Number
- NCT01125553
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Chula Vista, California, United States
Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 521
- Registration Number
- NCT01123980
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan
© Copyright 2025. All Rights Reserved by MedPath